ATYR PHARMA, INC.
NASDAQ: ATYR (aTyr Pharma, Inc.)
Last update: 4 hours ago1.02
-5.02 (-83.17%)
| Previous Close | 6.03 |
| Open | 1.26 |
| Volume | 152,601,536 |
| Avg. Volume (3M) | 4,927,075 |
| Market Cap | 99,456,400 |
| Price / Sales | 204.18 |
| Price / Book | 7.89 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.800 |
| Total Debt/Equity (MRQ) | 17.35% |
| Current Ratio (MRQ) | 7.80 |
| Operating Cash Flow (TTM) | -62.16 M |
| Levered Free Cash Flow (TTM) | -37.33 M |
| Return on Assets (TTM) | -39.82% |
| Return on Equity (TTM) | -79.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | aTyr Pharma, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.5 |
| Average | 0.63 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 69.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Federated Hermes, Inc. | 30 Jun 2025 | 14,666,600 |
| Integral Health Asset Management, Llc | 30 Jun 2025 | 1,050,000 |
| Point72 Asset Management, L.P. | 30 Jun 2025 | 988,677 |
| Ghost Tree Capital, Llc | 30 Sep 2024 | 800,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Wells Fargo, 2,363.05%) | Buy |
| Median | 21.00 (1,968.97%) | |
| Low | 17.00 (Jefferies, 1,574.88%) | Buy |
| Average | 21.00 (1,968.97%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 22 Aug 2025 | 17.00 (1,574.88%) | Buy | 5.35 |
| Wells Fargo | 20 Jun 2025 | 25.00 (2,363.05%) | Buy | 5.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Sep 2025 | Announcement | aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis |
| 05 Sep 2025 | Announcement | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Aug 2025 | Announcement | aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update |
| 22 Jul 2025 | Announcement | aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis |
| 26 Jun 2025 | Announcement | aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |